Small-cell lung cancer — Rapid | Doctor’s Passport

Synopsis

Recognise rapidly disseminating neuroendocrine lung cancer, stage thorax and brain promptly and coordinate time-sensitive chemoradiotherapy, systemic immunochemotherapy and paraneoplastic or supportive care.

SCLC is a high-grade neuroendocrine carcinoma strongly associated with smoking, rapid doubling, early nodal and blood spread and initial chemotherapy and radiation sensitivity.
Obtain adequate tissue quickly but avoid prolonged serial diagnostics; pathology should distinguish SCLC from NSCLC, carcinoid and large-cell neuroendocrine carcinoma.
First-line stage uses contrast CT chest and upper abdomen plus brain MRI, with PET-CT when it will refine a radical limited-stage field or resolve uncertainty.
Record both TNM and practical limited versus extensive stage: limited disease fits a tolerable radical thoracic radiotherapy field, whereas extensive disease has spread beyond it.
Preferred curative treatment for fit limited-stage SCLC is early concurrent platinum-etoposide chemoradiotherapy, commonly beginning thoracic radiotherapy with cycle one or two.
Extensive-stage first-line treatment commonly combines platinum-etoposide with an approved checkpoint inhibitor followed by maintenance immunotherapy under current NICE criteria.
Discuss prophylactic cranial irradiation or structured MRI surveillance after response according to stage, age, cognition, MRI findings and patient preference; do not apply it automatically.
Actively identify SIADH, ectopic ACTH, Lambert-Eaton syndrome, SVCO, thrombosis and treatment lysis because correcting complications can restore treatment fitness.

Key red flags

Stridor, monophonic wheeze, lobar collapse or severe haemoptysis suggests central airway involvement requiring urgent respiratory and interventional assessment.

Facial plethora, upper-limb swelling, orthopnoea or confusion suggests superior vena cava obstruction and possible cerebral venous compromise.

Seizure, focal deficit, headache with vomiting or altered consciousness indicates possible brain metastasis or severe hyponatraemia.

Marked hyponatraemia with confusion or seizure requires monitored emergency correction while SIADH and other causes are confirmed.

Proximal weakness, dry mouth and facilitated reflexes can precede cancer diagnosis through Lambert-Eaton myasthenic syndrome.

SVCO presentation

Facial and arm swelling, venous collaterals and positional head pressure from bulky mediastinal disease may require urgent stent or systemic treatment.

SIADH phenotype

Euvolaemic hyponatraemia with concentrated urine can cause nausea, falls, confusion or seizure and needs severity-based correction.

Brain metastatic disease

Headache, focal deficit, seizure, gait change or cognitive decline requires urgent brain imaging and raised-pressure assessment.

Investigation priorities

Core or bronchoscopic tissue diagnosisFirst step

Confirm high-grade small-cell neuroendocrine morphology and exclude other lung and metastatic cancers.

First-line contrast CT chest and upper abdomenFirst line

Define primary, nodal, pleural, liver and adrenal disease rapidly and identify complications.

Management branches

Stage quicklyAnswer limited versus extensive disease

Pathology confirms or strongly supports SCLC.

Obtain contrast CT and brain MRI promptly, adding PET-CT when it can refine a planned radical field or clarify one decisive site.
Record TNM and whether all known disease fits a tolerable thoracic radiotherapy volume and assess performance, lung, renal, hearing and paraneoplastic complications.
Discuss at the thoracic MDT without allowing avoidable serial tests to postpone a time-sensitive first treatment cycle.

Key medicines

Platinum with etoposideA common 21-day specialist regimen gives cisplatin 75 mg/m² intravenously on day 1 with etoposide 100 mg/m² intravenously on days 1 to 3 for four cycles, with carboplatin substituted by protocol when renal, hearing or fitness factors require.Use the exact NHS protocol and adjust for kidney, hearing, neuropathy and marrow reserve; prevent emesis and monitor febrile neutropenia, thrombosis, electrolyte wasting and tumour lysis.

Atezolizumab with extensive-stage chemotherapyGive atezolizumab 1,200 mg intravenously every 3 weeks with carboplatin and etoposide for four cycles, then continue 1,200 mg every 3 weeks as maintenance under the licensed and current NICE-funded regimen.Screen autoimmune, transplant, infection and organ context and educate about delayed immune lung, bowel, liver, endocrine, cardiac, renal, skin and neurological toxicity; hold and treat according to grade.

Open full textbook →Answer 2 questions